Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Product liability

This article was originally published in The Gray Sheet

Executive Summary

Product liability: Senate fails twice to invoke cloture May 4 on a substitute amendment offered by Sen. Slade Gorton (R-Wash.) to the product liability bill, HR 956. The substitute is a heavily amended version of the original Gorton/Rockefeller bill (S 565). The first vote (46-53) to limit debate fell short of the necessary 60 votes, with two Democrats, Sens. Joseph Lieberman (Conn.) and James Exon (Neb.), breaking ranks. In the second vote (47-52), Republican Strom Thurmond (S.C.) switched his vote in favor of cloture. Senate Majority Leader Robert Dole (R-Kan.) indicated before the votes that in the event of no cloture, another Gorton/Rockefeller amendment would be considered as a substitute; GOP leadership indicated that the measure is likely to be considered again the week of May 8...

You may also be interested in...



Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Interview: Double Delight For ImmuPharma's Dimitriou

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.

UsernamePublicRestriction

Register

MT004064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel